Literature DB >> 19452130

In vitro gastrointestinal lipolysis of four formulations of piroxicam and cinnarizine with the self emulsifying excipients Labrasol and Gelucire 44/14.

Sylvie Fernandez1, Stéphanie Chevrier, Nicolas Ritter, Bruno Mahler, Frédéric Demarne, Frédéric Carrière, Vincent Jannin.   

Abstract

PURPOSE: Labrasol and Gelucire 44/14 are defined admixtures of acylglycerols and PEG esters which are substrates for digestive lipases.
METHODS: We investigated their in vitro gastrointestinal lipolysis to understand which compounds are, after digestion, responsible for keeping poorly water-soluble drugs in solution. The precipitation of piroxicam and cinnarizine formulated in these excipients during the gastrointestinal lipolysis was also studied.
RESULTS: Monoacylglycerols and PEG monoesters are the largest compounds present at the end of gastric phase whereas PEG-monoesters are the largest compounds after the duodenal phase. The precipitation of piroxicam is mainly due to the gastric lipolysis. In the control experiments performed without digestive lipases, cinnarizine formulated in Labrasol was found to precipitate upon dilution of the gastric medium to form the solution mimicking the duodenal medium. In the presence of gastric lipase, Labrasol was hydrolyzed and the precipitation of cinnarizine was not observed in this case. When the cinnarizine was formulated with Gelucire 44/14 the precipitation was only due to the dilution of the gastric medium.
CONCLUSION: Our study highlights the importance of the gastrointestinal lipolysis and the associated phenomena such as the dilution of chyme by biliary and pancreatic secretions in vivo, on the solubilisation of poorly water-soluble drugs formulated with lipid-based excipients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19452130     DOI: 10.1007/s11095-009-9906-2

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  50 in total

1.  A new method for dissolution studies of lipid-filled capsules employing nifedipine as a model drug.

Authors:  V Pillay; R Fassihi
Journal:  Pharm Res       Date:  1999-02       Impact factor: 4.200

2.  Albendazole generics--a comparative in vitro study.

Authors:  E Galia; J Horton; J B Dressman
Journal:  Pharm Res       Date:  1999-12       Impact factor: 4.200

3.  Dissolution of ionizable water-insoluble drugs: the combined effect of pH and surfactant.

Authors:  J Jinno; D m Oh; J R Crison; G L Amidon
Journal:  J Pharm Sci       Date:  2000-02       Impact factor: 3.534

4.  Improved solubility and dissolution rate of piroxicam using gelucire 44/14 and labrasol.

Authors:  Ayşegül Karataş; Nilüfer Yüksel; Tamer Baykara
Journal:  Farmaco       Date:  2005-09

5.  Importance of human gastric lipase for intestinal lipolysis: an in vitro study.

Authors:  Y Gargouri; G Pieroni; C Rivière; P A Lowe; J F Saunière; L Sarda; R Verger
Journal:  Biochim Biophys Acta       Date:  1986-12-05

6.  Disposition of lipid-based formulation in the intestinal tract affects the absorption of poorly water-soluble drugs.

Authors:  Kazunori Iwanaga; Toshihiro Kushibiki; Makoto Miyazaki; Masawo Kakemi
Journal:  Biol Pharm Bull       Date:  2006-03       Impact factor: 2.233

7.  Further biochemical characterization of human pancreatic lipase-related protein 2 expressed in yeast cells.

Authors:  Cécilia Eydoux; Josiane De Caro; Francine Ferrato; Paul Boullanger; Dominique Lafont; René Laugier; Frédéric Carrière; Alain De Caro
Journal:  J Lipid Res       Date:  2007-03-30       Impact factor: 5.922

8.  Separation and characterization of the colloidal phases produced on digestion of common formulation lipids and assessment of their impact on the apparent solubility of selected poorly water-soluble drugs.

Authors:  Greg A Kossena; Ben J Boyd; Christopher J H Porter; William N Charman
Journal:  J Pharm Sci       Date:  2003-03       Impact factor: 3.534

9.  Enhanced bioavailability of piroxicam using Gelucire 44/14 and labrasol: in vitro and in vivo evaluation.

Authors:  Nilüfer Yüksel; Aysegül Karataş; Yalçin Ozkan; Ayhan Savaşer; Sibel A Ozkan; Tamer Baykara
Journal:  Eur J Pharm Biopharm       Date:  2003-11       Impact factor: 5.571

10.  Pancreatic lipase-related protein 1 (PLRP1) is present in the pancreatic juice of several species.

Authors:  J De Caro; F Carrière; P Barboni; T Giller; R Verger; A De Caro
Journal:  Biochim Biophys Acta       Date:  1998-09-08
View more
  10 in total

Review 1.  Effects of surfactants on lipase structure, activity, and inhibition.

Authors:  Vincent Delorme; Rabeb Dhouib; Stéphane Canaan; Frédéric Fotiadu; Frédéric Carrière; Jean-François Cavalier
Journal:  Pharm Res       Date:  2011-01-14       Impact factor: 4.200

2.  Lipid-based oral delivery systems for skin deposition of a potential chemopreventive DIM derivative: characterization and evaluation.

Authors:  Cedar H A Boakye; Ketan Patel; Apurva R Patel; Henrique A M Faria; Valtencir Zucolotto; Stephen Safe; Mandip Singh
Journal:  Drug Deliv Transl Res       Date:  2016-10       Impact factor: 4.617

3.  In vitro lipolysis data does not adequately predict the in vivo performance of lipid-based drug delivery systems containing fenofibrate.

Authors:  Nicky Thomas; Katharina Richter; Thomas B Pedersen; René Holm; Anette Müllertz; Thomas Rades
Journal:  AAPS J       Date:  2014-04-02       Impact factor: 4.009

Review 4.  Lipids in the Stomach - Implications for the Evaluation of Food Effects on Oral Drug Absorption.

Authors:  Mirko Koziolek; Frédéric Carrière; Christopher J H Porter
Journal:  Pharm Res       Date:  2018-02-08       Impact factor: 4.200

Review 5.  Current Status of Supersaturable Self-Emulsifying Drug Delivery Systems.

Authors:  Heejun Park; Eun-Sol Ha; Min-Soo Kim
Journal:  Pharmaceutics       Date:  2020-04-16       Impact factor: 6.321

6.  Effect of ingested lipids on drug dissolution and release with concurrent digestion: a modeling approach.

Authors:  Fulden Buyukozturk; Selena Di Maio; David E Budil; Rebecca L Carrier
Journal:  Pharm Res       Date:  2013-12       Impact factor: 4.200

7.  Toward the establishment of standardized in vitro tests for lipid-based formulations. 5. Lipolysis of representative formulations by gastric lipase.

Authors:  Jean-Claude Bakala-N'Goma; Hywel D Williams; Philip J Sassene; Karen Kleberg; Marilyn Calderone; Vincent Jannin; Annabel Igonin; Anette Partheil; Delphine Marchaud; Eduardo Jule; Jan Vertommen; Mario Maio; Ross Blundell; Hassan Benameur; Anette Müllertz; Colin W Pouton; Christopher J H Porter; Frédéric Carrière
Journal:  Pharm Res       Date:  2014-10-07       Impact factor: 4.200

8.  In vitro digestion of the self-emulsifying lipid excipient Labrasol(®) by gastrointestinal lipases and influence of its colloidal structure on lipolysis rate.

Authors:  Sylvie Fernandez; Vincent Jannin; Stéphanie Chevrier; Yann Chavant; Frédéric Demarne; Frédéric Carrière
Journal:  Pharm Res       Date:  2013-05-02       Impact factor: 4.200

9.  A new strategy for enhancing the oral bioavailability of drugs with poor water-solubility and low liposolubility based on phospholipid complex and supersaturated SEDDS.

Authors:  Hui Zhou; Jiangling Wan; Lei Wu; Tao Yi; Wei Liu; Huibi Xu; Xiangliang Yang
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

10.  The Influence of Fed State Lipolysis Inhibition on the Intraluminal Behaviour and Absorption of Fenofibrate from a Lipid-Based Formulation.

Authors:  Marlies Braeckmans; Joachim Brouwers; Danny Riethorst; Cécile Servais; Jan Tack; Patrick Augustijns
Journal:  Pharmaceutics       Date:  2022-01-04       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.